The latest in health it & security: 6 developments from the past day, tracked and curated by the HealthTech Cube news desk. The lead story: Where Are the Biggest Opportunities in Women’s Cardiovascular Health?.
Where Are the Biggest Opportunities in Women’s Cardiovascular Health?
MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health. The post Where Are the Biggest Opportunities in Women’s Cardiovascular Health? appeared first on MedCity News.
Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill
Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD. The post Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill …
Follow the full firehose on the HTC Wire, refreshed automatically every day.